Mayo Clinic Laboratories > Neurology

PUSHING THE BOUNDARIES OF NEUROLOGY DIAGNOSIS

Mayo Clinic Laboratories is leading an evolution in neurology testing. Propelled by ongoing discoveries of clinically relevant biomarkers, our laboratory scientists integrate research findings into test development and implementation. Collaboration between our labs and the clinical practice at Mayo Clinic supports development of clinically validated testing that delivers actionable answers for patients.

Answers From the Lab Revolutionary Technology Advances Diagnosis of Neurodegenerative Disorders
Eye on Innovation Neurofilament light chain test helps in diagnosis, treatment, and prognosis of ALS and MS
Patient Spotlight Innovative SORD test provides clarity for two young patients
Case Study Promoting laboratory stewardship through clinical decision support
Patient Spotlight Rare patient case helps inform and validate GABA-A-R antibody encephalitis testing: JoAnne Michael

NEUROLOGY TEST SPECIALTIES

Autoimmune disorders Autoimmune disorders
Autoimmune disorders

Covering the spectrum of autoimmune neurological disorders, our evaluations apply a phenotype-specific approach to diagnose and guide treatment for patients affected by immune-mediated neurological illness.

Biopharma testing Biopharma testing
Biopharma testing

With 19 subspecialty labs that perform neurology testing, we are at the forefront of research that integrates novel biomarker discoveries into our evaluations. Our menu, including testing for Alzheimer’s disease, dementia, and autoimmune conditions, provides partners with results that move solutions through the development pipeline.

Demyelinating disease Demyelinating disease
demyelinating disease

We offer sensitive and specific testing to diagnose a range of demyelinating diseases, from classic multiple sclerosis (MS) to atypical MS, AQP4/MOG-associated disorders, and spinal cord disorders.

Dementia Dementia
Dementia

Offering the industry’s most sophisticated suite of testing available, including biomarker evaluations, autoimmune panels, testing for rapidly progressive cases, and an innovative combination assay, Mayo Clinic Laboratories is a one-stop laboratory solution for dementia and Alzheimer’s disease testing.

Epilepsy Epilepsy
Epilepsy

We offer testing that identifies genetic and autoimmune causes of epilepsy. With testing developed by neurologists, epileptologists, and geneticists, physicians can determine the causes of epilepsy in their patients and identify potential treatment options.

Movement disorders Movement disorders
Movement disorders

Our comprehensive movement disorder testing includes an autoimmune movement disorders panel that contains the latest newly discovered clinically actionable antibodies. We also offer hereditary movement disorders testing that covers ataxia, Huntington's disease, Parkinson's disease, and more.  

Neurogenetics Neurogenetics
Neurogenetics

A multidisciplinary team of clinical neurology experts, laboratory scientists, and genetic counselors work collaboratively to develop and implement our neurogenetic testing. Covering the full range of neurogenetic illness, our testing is unparalleled in scope and detail and uses an algorithmic and phenotypic approach that ensures the right patient receives the right test at the right time.

Neuromuscular disorders Neuromuscular disorders
Neuromuscular disorders

Our comprehensive menu of precision testing enables physicians to diagnose and manage patients with disorders such as myasthenia gravis, Lambert-Eaton syndrome, immune-mediated necrotizing myopathy, hereditary myopathy, and more.

Pediatrics Pediatrics
Pediatrics

Including evaluations for autoimmune central nervous system disorders, multiple sclerosis, and narcolepsy, our data-driven pediatric testing provides precision results to guide treatment and place young patients on the path to healing.

Peripheral neuropathy Peripheral neuropathy
Peripheral neuropathy

We offer testing to identify peripheral autoimmune neuropathy with axonal or demyelinating causes, as well as next-generation sequencing to help establish whether a peripheral neuropathy is genetic in nature.

“The ability of Mayo Clinic to make discoveries and translate these into solutions for our patients is critical to our mission.”

John Mills, Ph.D., co-director, Neuroimmunology Laboratory

OUR DIFFERENCE

Clinically driven neurology test menu
Consolidate more of your sendout testing to one trusted lab.

Solving the most complex neurologic cases
We continually innovate to develop new testing approaches that enable answers to the rarest and most complex neurological conditions.

Backed by the world’s leading experts
Our laboratories are led by clinical neurologists who have extensive experience using testing to guide and directly impact patient care. These experts interpret each evaluation, providing clinically actionable answers, not just results.

News and updates

The latest

A journey to diagnosis: One patient’s story of resilience and hope

For many, the path to a correct diagnosis can be long and filled with uncertainty. This story highlights the resilience and determination of one patient who navigated a complex medical journey to find answers and hope at Mayo Clinic. The patient asked to remain anonymous for personal privacy reasons.

Learn more
Epic journey yields unique offering

The quest to create a test pinpointing the source of the rare, testicular cancer-associated illness successfully concluded in the summer of 2021.

Glimmer of Hope: Gregor Heinrich

While Gregor Heinrich never could have imagined that testicular cancer was related to his problems with his vision and gait, learning he was positive for KLHL11 protein biomarkers meant he could receive treatment for both the cancer and the illness behind it.

Reversing a dire disorder: Lorinda McKinley

Advanced testing at Mayo Clinic Laboratories that confirmed a diagnosis of myasthenia gravis put Lorinda McKinley on the road to renewed health after she nearly lost it all to the rare autoimmune disease.

Neurofascin 155 IgG4 Antibody Test [Test in Focus]

John Mills, Ph.D., explains Mayo Clinic Laboratories' new neurofascin 155 (NF155) IgG4 antibody test, which is the first commercially available test in the U.S. to use flow cytometry to detect for NF155 antibodies and confirm diagnosis of CIDP.

Mitochondrial Disease [Test in Focus]

Linda Hasadsri, M.D., Ph.D., explains how Mayo Clinic Laboratories’ inclusive approach to mitochondrial disease testing expedites diagnosis. Using innovative methodologies like custom reagents and droplet digital PCR enables precision insights on prognosis and treatment options.

Shining light on one family’s struggle: Barbara, Deborah, Pamela, and Rylie

Before testing at Mayo Clinic Laboratories, Barbara Domaille, Deborah Neville, Pamela Neville, and Rylie Ronnenberg thought there could be a genetic connection to the hip problems they shared. After the testing, they knew for sure.

MAG Antibody Testing [Test in Focus]

John Mills, Ph.D., explains Mayo Clinic Laboratories’ approach to MAG antibody testing. The ELISA-based assay uses higher reference ranges and human MAG antigen to detect MAG antibodies, which are associated with a rare, hard-to-treat condition known as DADS neuropathy.

Kelch-like protein 11 autoantibodies: A novel biomarker of testicular cancer associated neurological autoimmunity

This “Specialty Testing” webinar will discuss the collaborative effort which led to the discovery of Kelch like protein 11 (KLHL11) IgG as a specific biomarker of neurological autoimmunity associated testicular germ cell tumor.

Kelch-11 Autoantibody Test [Test in Focus]

Divyanshu (Div) Dubey, M.B.B.S., explains how Mayo Clinic Labs’ new Kelch-11 antibody test — the first in the world — can confirm diagnosis, guide treatment, and improve outcomes in patients affected by testicular cancer-associated paraneoplastic encephalitis.

Mayo Clinic Laboratories offers first test to detect recently discovered autoimmune disease associated with testicular cancer

Mayo Clinic Laboratories has launched a first-in-the-U.S. autoimmune test of the Kelchlike protein 11 antibody, or KLHL11, which is used to detect autoimmune disease associated with testicular cancer.

Week in Review: June 11

Top highlights include: which insurance companies cover the new Alzheimer's drug, advice on how to talk to someone who is hesitant to get the COVID-19 vaccine, employers requiring you to be vaccinated, FDA approval Alzheimer drug, MN COVID-19 numbers heading in the right direction, having "brain frog" and blaming the pandemic.

Neuroimmunology: Updates and antibody test utilization

In this month’s “Hot Topic,” Andrew McKeon, M.B., B.Ch., M.D., reviews the use of neurological phenotype-based evaluations, the move away from the paraneoplastic evaluation, and upcoming changes to test profiles.

View More
Resources
Download Neurology test request form
Delivering specialized testing and consultative support for:
Learn more Commercial laboratories
Learn more Global healthcare
Learn more Hospitals and health systems

LEARN MORE ABOUT HOW WE CAN BUILD YOUR LAB'S POTENTIAL.

INTERESTED IN LEARNING MORE?

Fill out the form below and one of our specialists will be in touch.

Are you a patient? Click here.

(BETA) Choose a language to view this content in:
About the translation.